DK141531B - Analogous procedure for the preparation of 1-methyl-9,10-dihydro-d-lysergic acid allylamide or acid addition salts thereof. - Google Patents

Analogous procedure for the preparation of 1-methyl-9,10-dihydro-d-lysergic acid allylamide or acid addition salts thereof. Download PDF

Info

Publication number
DK141531B
DK141531B DK51373AA DK51373A DK141531B DK 141531 B DK141531 B DK 141531B DK 51373A A DK51373A A DK 51373AA DK 51373 A DK51373 A DK 51373A DK 141531 B DK141531 B DK 141531B
Authority
DK
Denmark
Prior art keywords
lysergic acid
acid
methyl
dihydro
lysergic
Prior art date
Application number
DK51373AA
Other languages
Danish (da)
Other versions
DK141531C (en
Inventor
Tibor Balogh
Lajos Wolf
Emilia Uskert
Jozsef Borsi
Erzsebet Mago
Original Assignee
Richter Gedeon Vegyeszet
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from HUGO001186 external-priority patent/HU164051B/hu
Priority claimed from HUGO001187 external-priority patent/HU163546B/hu
Application filed by Richter Gedeon Vegyeszet filed Critical Richter Gedeon Vegyeszet
Publication of DK141531B publication Critical patent/DK141531B/en
Application granted granted Critical
Publication of DK141531C publication Critical patent/DK141531C/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D457/00Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
    • C07D457/04Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 8
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D457/00Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
    • C07D457/04Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 8
    • C07D457/06Lysergic acid amides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D457/00Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
    • C07D457/04Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 8
    • C07D457/06Lysergic acid amides
    • C07D457/08Lysergic acid amides in which the amide nitrogen is a member of a heterocyclic ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Description

\fia, (11) FREMLÆeeELSESSKRIFT 141531 DANMARK lnt C| a c 07 D 457/06 • (2!) Antegning nr. 515/75 (22) »ndtovwetden 51 · J?°* 1975 (23) Lebedag 51- Jan. 1975 (44) Antegningen fremlagt og . ιηΟΛ\ via, (11) PUBLICATION 141531 DENMARK lnt C | a c 07 D 457/06 • (2!) Note No. 515/75 (22) »ndtovwetden 51 · J? ° * 1975 (23) Life Day 51- Jan. 1975 (44) The note presented and. ιηΟΛ

fremleeggeleeeekrtft«oflantHggjortden 14. apr. lytHJsubmitting lectures «oflantHggjortden Apr 14 lytHJ

DIREKTORATET FOR t _ PATENT-OG VAREMÆRKEVÆSENET <*» Prioritet begeewt fra denDIRECTORATE OF T _ PATENT AND TRADEMARK <* »Priority moved from the

4. feb. 1972, GO 1186, HUFeb 4 1972, GO 1186, HU

4. feb. 1972, GO 1187, HUFeb 4 1972, GO 1187, HU

(71) RICHTER GEDEON VEGYESZETI GBR RT., 19-21, Gyoemroel ut, Budapest X# HU.(71) RICHTER GEDEON VEGYESZETI GBR RT., 19-21, Gyoemroel ut, Budapest X # HU.

(72) Opfinder: Erzeebet Mago, 18, Karinthy Frigyes ut, Budapest XI, HU:(72) Inventor: Erzeebet Mago, 18, Karinthy Frigyes ut, Budapest XI, HU:

Tibor Balogh, 47a, Ealocsai u., Budapest XIV, HU: Emilia Uskert, 8,Tibor Balogh, 47a, Ealocsai u., Budapest XIV, HU: Emilia Uskert, 8,

Vali u., Budapest XI, HU: Jozsef Borsi, 90# Bartok Bela u¥, Budapest XI, HU: Lajos Wolf, 28b, NemetvoeTgyl u., Budapest XII, HU.Vali u., Budapest XI, HU: Jozsef Borsi, 90 # Bartok Bela u ¥, Budapest XI, HU: Lajos Wolf, 28b, NemetvoeTgyl u., Budapest XII, HU.

(74) Fuldmagtlg under segens behandling:(74) Power of Attorney during the process of blessing:

Kontor for Industriel Eneret v. Svend Sohønning._, (54) Analogifremgangsmåde til fremstilling af 1 -metyl-9, IQ-dihydro-d-ly5* sergsyreallylamid eller syreadditionsealte deraf.Office of Industrial Energetic v. Svend Sohønning.

Den foreliggende opfindelse angår en fremgangsmåde til fremstilling af den hidtil ukendte forbindelse l-metyl-9,10-di-hydro-d-lysergsyreallylamid med den i kraV l’s indledning viste formel I eller syreadditionssalte deraf.The present invention relates to a process for the preparation of the novel compound 1-methyl-9,10-di-hydro-d-lysergic acid allylamide with the formula I or acid addition salts thereof shown in claim 1.

Som bekendt er lysergsyreamider forbindelser med stor medicinsk betydning. Således er £. eks. alle de ergot-alkaloider, der forekommer i naturen,lysergsyreamider.' De halvsyntetiske processer der går ud fra lysergsyre tager i de fleste tilfælde sigte på fremstilling af lysergsyreamider og lysergsyrealkanolamider eftersom disse forbindelser kan udvide lysergsyrederivaternes terapeutiske anvendelighed i høj grad.As you know, lysergic acid amides are compounds of great medical importance. Thus, £. eg all the ergot alkaloids found in nature, lysergic acid amides. ' The semi-synthetic processes based on lysergic acid are in most cases aimed at the preparation of lysergic acid amides and lysergic acid alkanolamides since these compounds can greatly extend the therapeutic utility of the lysergic acid derivatives.

Der er blevet udviklet adskillige processer til halvsyntetisk fremstilling af lysergsyreamider. Den første af de vidt udbredte metoder udarbejdedes af A. Stoll og A. Hofman (Helv. Chim.Several processes have been developed for the semi-synthetic production of lysergic acid amides. The first of the widely used methods was devised by A. Stoll and A. Hofman (Helv. Chim.

2 1415312 141531

Acta 26, 944, 1943). Ved denne fremgangsmåde spaltedes lysergsy-repeptider til dannelse af lysergsyrehydrazid, denne sidstnævnte forbindelse omdannedes til lysergsyreazid hvilken forbindelse anvendtes til acylering af forskellige amider. En stor ulempe ved denne såkaldte azidmetode består imidlertid i at den skrider frem med dårligt udbytte og at der også dannes en betydelig mængde biprodukter.Acta 26, 944, 1943). In this process, lysergic acid peptides were cleaved to form lysergic acid hydrazide, this latter compound being converted to lysergic acid azide which was used to acylate various amides. However, a major disadvantage of this so-called azide method is that it proceeds with poor yield and that a considerable amount of by-products are also formed.

En anden kendt proces er den såkaldte blandede anhydrid-koblingsmetode. Ved denne fremgangsmåde dannes der et blandet an-hydrid af lysergsyre og trifluoreddikesyre (USA patentskrift nr. 2.736.728) eller af lysergsyre og svovltrioxyd (tysk patentskrift nr. 1.040.560), og det dannede blandede anhydrid anvendes til acylering af alkano laminer. Denne proces muliggør imidlertid ikke fremstilling af ensartede lysergsyrealkanolamider.Another known process is the so-called mixed anhydride coupling method. In this process, a mixed anhydride is formed of lysergic acid and trifluoroacetic acid (U.S. Patent No. 2,736,728) or of lysergic acid and sulfur trioxide (German Patent No. 1,040,560) and the resulting mixed anhydride is used for acylation of alkano laminates. However, this process does not allow the production of uniform lysergic acid alkanolamides.

Ved en yderligere kendt fremgangsmåde udføres acylerin-gen med lysergsyrehalogenider. Fremstilling af de respektive ly-sergsyrehalo geni der er beskrevet i de ungamske patentskrifter nr.In a further known method, the acylation with lysergic acid halides is carried out. Preparation of the respective Lysergic Acid Halo Genes disclosed in the Unamanian Patent Specification no.

150.425 og 151.847. Disse processer er imidlertid ufordelagtige i mange henseender; således kan f. eks. syrekloriddannelsen kun udføres under yderst aggressive reaktionsbetingelser (f. eks. ved anvendelse af fosfortriklorid som opløsningsmiddel og fosforoxy-klorid og fosforpentaklorid som kloreringsmiddel), og det dannede syreklorid indeholder store mængder urenheder (frem for alt lysergsyre, uorganiske fosforforbindelser og lysergsyreklorid der tillige er kloreret i stilling 2), og endelig kendes der ingen • proces til rensning af syrekloridet. Desuden kan acylering under anvendelse af lysergsyreklorid kun udføres med et udbytte på højst 10%, og urenhederne i lysergsyrekloridet viser sig også i de lyser gsyreami der , der fremstilles på denne måde.150,425 and 151,847. However, these processes are disadvantageous in many respects; Thus, for example, acid chloride formation can only be carried out under extremely aggressive reaction conditions (e.g., using phosphorus trichloride as solvent and phosphorus oxychloride and phosphorus pentachloride as chlorinating agent), and the resulting acid chloride contains large amounts of impurities (especially lysergic acid, inorganic phosphorus compounds, and lysergic acid chloride, which is also chlorinated in position 2), and finally there is no known process for purifying the acid chloride. In addition, acylation using lysergic acid chloride can only be performed with a yield of not more than 10%, and the impurities in the lysergic acid chloride also appear in the lighter gaseous amines produced in this way.

Østrigsk patentskrift nr. 216.679 beskriver en fremgangsmåde til fremstilling af monosubstituerede lysergsyreamider, ved hvilken fremgangsmåde lysergsyre og en primær amin kondenseres med hinanden i nærværelse af karbodiimider. Ved anvendelse af denne reaktion kan der imidlertid ikke opnås stort udbytte eftersom den optisk aktive lysergsyre næsten fuldstændigt omdannes til den racemiske form under reaktionens forløb.Austrian Patent Specification No. 216,679 discloses a process for the preparation of monosubstituted lysergic acid amides in which the process of lysergic acid and a primary amine is condensed with each other in the presence of carbodiimides. However, using this reaction, great yield cannot be obtained since the optically active lysergic acid is almost completely converted to the racemic form during the course of the reaction.

Der kendes også andre fremgangsmåder til fremstilling af lysergsyrealkanolamider, nemlig den direkte kondensation af lysergsyre med aminoalkoholer (Collection 31, 3415, 1966), samt 3 141831 amidering af lysergsyremetylester (Collection 22, 1014, 1957).Other methods are also known for preparing lysergic acid alkanolamides, namely the direct condensation of lysergic acid with amino alcohols (Collection 31, 3415, 1966), and amidation of lysergic acid methyl ester (Collection 22, 1014, 1957).

Disse processer fordrer imidlertid meget høje temperaturer (190-200°C) og lange reaktionstider (otte til ti timer), og de forløber med yderst lave udbytter.However, these processes require very high temperatures (190-200 ° C) and long reaction times (eight to ten hours), and they proceed with extremely low yields.

Det har nu vist sig at man med fordel kan fremstille den omhandlede forbindelse i fuldstændig ren tilstand når en aktiv lysergsyreester omsættes med allylamin, dvs. ved en fremgangsmåde der i princippet er kendt fra peptidkemien. Der sker hverken iso-merisering eller racemering under reaktionens forløb, og syntesen skrider frem med næsten kvantitativt udbytte.It has now been found that it is advantageous to prepare the subject compound in a completely pure state when an active lysergic acid ester is reacted with allylamine, ie. by a method known in principle from the peptide chemistry. Neither isomerization nor racemization occurs during the course of the reaction, and the synthesis proceeds with almost quantitative yield.

I overensstemmelse hermed er fremgangsmåden ifølge opfindelsen ejendommelig ved det i krav l's kendetegnende del anførte. Særlig højt bliver udbyttet, hvis man ifølgé opfindelsen går frem som angivet i krav 2, og særlig simpel bliver syntesen hvis man undlader at isolere den aktive ester og altså ifølge opfindelsen går frem som angivet i krav 3.Accordingly, the method of the invention is peculiar to the characterizing part of claim 1. The yield is particularly high if one according to the invention proceeds as set forth in claim 2, and particularly simple becomes the synthesis if one fails to isolate the active ester and thus according to the invention proceeds as set forth in claim 3.

Den omhandlede forbindelse har specifik anti-serotonin-aktivitet, en virkning der også findes hos de fra dansk patent nr.The subject compound has specific anti-serotonin activity, an effect also found in those of Danish patent no.

107 229 og dansk franlæggelsesskrlft nr. 117 501 kendte lysergsyneamfder. ved forsøg på isolerede organer under in vitro betingelser ihhiberer disse forbindelser serotonins aktivitet med hensyn til kontraktion af glatte muskler j·. mens forbindelsen under in vivo betingelser i lave doser antagoniserer den ødeminducerende og cirkulationspåvirkende effekt af serotonin. Desuden udøver forbindelsen overraskende antidepressiv virkning på centralnervesystemet af lignende art som de tricykliske anti-depressanter; således antagoniserer den i doser på 2,5-10 mg/kg intraperitonealt og oralt hos rotter og mus de neuroleptiske egenskaber af reserpin og tetrabenazin. Den potentierer den psykostimu-lerende virkning af amfetamin. Disse forbindelser afviger imidlertid fra de tricykliske antidepressanter ved ikke at forøge noradrenalins vasopressoraktivitet.107 229 and Danish Disposal Gazette No. 117 501 known light energy officials. when tested for isolated organs under in vitro conditions, these compounds inhibit serotonin activity in smooth muscle contraction. whereas the compound, under in vivo conditions at low doses, antagonizes the edema-inducing and circulating effects of serotonin. In addition, the compound exerts surprising antidepressant effect on the central nervous system similar to the tricyclic anti-depressants; thus, at doses of 2.5-10 mg / kg, it antagonizes intraperitoneally and orally in rats and mice the neuroleptic properties of reserpine and tetrabenazine. It potentiates the psychostimulatory effect of amphetamine. However, these compounds differ from the tricyclic antidepressants by not increasing the vasopressor activity of norepinephrine.

Forbindelserne med den almene formel II, der anvendes som udgangsforbindelser ved fremgangsmåden ifølge opfindelsen, kan fremstilles ved omsætning af l-metyl-9,10-dihydrolysergsyre med formel IIIThe compounds of general formula II used as starting compounds in the process of the invention can be prepared by reacting 1-methyl-9,10-dihydrolyseric acid of formula III

4 1415314 141531

OC - OHOC - OH

/ -\ 111 CH3 med en fenol med den almene formel hvor Z og n har de ovenfor anførte betydninger, i nærværelse af et dehydrati s eringsmi ddel.With a phenol of the general formula wherein Z and n have the meanings set forth above, in the presence of a dehydrating agent.

Blandt de aktiye lysergsyreestere kan pentaklorfenylesteren som nævnt anvendes med særlig fordel. Reaktionen udføres fortrinsvis i nærværelse af et inaktivt opløsningsmiddel som fx tetrahy-drofuran, acetonitril, metylenklorid eller dimetylformamid.Among the active lysergic acid esters mentioned above, the pentachlorophenyl ester can be used with particular advantage. The reaction is preferably carried out in the presence of an inert solvent such as tetrahydrofuran, acetonitrile, methylene chloride or dimethylformamide.

Fremgangsmåden ifølge opfindelsen skal i det følgende belyses ved et udførelseseksempel.The method according to the invention will now be illustrated by an exemplary embodiment.

Eksempel l-Metyl-9,10-dihydro-d-lysergsyre- allylamid 5,53 g l-metyl-9,10-dihydro-d-lysergsyre-pentaklorfenolester opløses i 100 ml tør kloroform under omrøring, hvorefter opløsningen afkøles med isvand og der tilsættes dråbevis 1,0 g 1-allylamin opløst i 10 ml kloroform. Opløsningen omrøres ved stuetemperatur i en time hvorefter den ekstraheres med 6 x 25 ml l/6s vandig vinsyreopløsning. De vandige ekstrakter forenes og de forenede ekstrakters pH-værdi reguleres til 8 ved tilsætning af nogle ml 10%s vandig ammoniumhydroxydopløsning. Den vandige op- 5 14153Ί løsning rystes med 5 x 50 ml kloroform. Kloroformopløsningerne forenes og tørres over natriumsulfat, filtreres og inddampes i vakuum. Remanensen opløses i 10 ml benzen og benzenopløsningen udhældes i 300 ml tør petroleumsæter. Det udskilte bundfald fra-filtreres, vaskes med en ringe mængde petroleumsæter og tørres i vakuum. Produktet underkastes kromatografering på en aluminium-oxydkolonne under anvendelse af en 8:2 blanding af kloroform og benzen som elueringsmiddel. På denne måde vindes 3,1 g (96¾) 1-metyl-9,10-dihydro-d-lysergsyre-allylamid Brød smeltepunkt 189°C.Example 1-Methyl-9,10-dihydro-d-lysergic acid allylamide 5.53 g of 1-methyl-9,10-dihydro-d-lysergic acid pentachlorophenol ester are dissolved in 100 ml of dry chloroform with stirring, after which the solution is cooled with ice water and 1.0 g of 1-allylamine dissolved in 10 ml of chloroform are added dropwise. The solution is stirred at room temperature for one hour and then extracted with 6 x 25 ml of 1 / 6s aqueous tartaric acid solution. The aqueous extracts are combined and the pH of the combined extracts is adjusted to 8 by the addition of a few ml of 10% aqueous ammonium hydroxide solution. The aqueous solution is shaken with chloroform (5 x 50 ml). The chloroform solutions are combined and dried over sodium sulfate, filtered and evaporated in vacuo. The residue is dissolved in 10 ml of benzene and the benzene solution is poured into 300 ml of dry petroleum ether. The precipitated precipitate is filtered off, washed with a small amount of petroleum ether and dried in vacuo. The product is chromatographed on an alumina column using an 8: 2 mixture of chloroform and benzene as the eluent. In this way 3.1 g (96¾) of 1-methyl-9,10-dihydro-d-lysergic acid allylamide is obtained. Melting point 189 ° C.

Udgangsforbindelsen, l-metyl-9,10-dihydro-d-lysergsyre-pentaklorfenolester fremstilles på følgende måde: 1,43 g l-metyl-9,10-dihydri-d-lysergsyre, der er fri for vand, suspenderes i en blanding af 60 ml absolut tetrahydro-furan og 60 ml absolut diklormetan hvorefter der tilsættes 1,35 g pentaklorfenol. Den dannede opløsning afkøles under omrøring til en temperatur mellem 0 og 5°C og i løbet af to timer tilsættes der i små portioner 1,25 g di cyk1ohexylk arbo di imid. Opløsningen opvarmes gradvis til 20°C og omrøres i yderligere to timer.The starting compound, 1-methyl-9,10-dihydro-d-lysergic acid pentachlorophenol ester is prepared as follows: 1.43 g of 1-methyl-9,10-dihydri-d-lysergic acid, which is water-free, is suspended in a mixture of 60 ml of absolute tetrahydrofuran and 60 ml of absolute dichloromethane, after which 1.35 g of pentachlorophenol is added. The resulting solution is cooled with stirring to a temperature between 0 and 5 ° C and over two hours, 1.25 g of di-cyclohexylc arbo di imide are added in small portions. The solution is gradually heated to 20 ° C and stirred for a further two hours.

Det dicyklohexylurinstof der fraskilles i krystallinsk form, filtreres og vaskes med 10 ml tetrahydrofuran. Filtratet og vaskevæsken forenes og inddampes til tørhed under nedsat tryk. Den tørre remanens opløses i varm tilstand i 5 ml benzen og den dannede opløsning udhældes under omrøring i 50 ml petroleumsæter. Den dannede suspension behandles med is i 24 timer hvorefter produktet filtreres, vaskes med 20 ml kold petroleumsæter og tørres under va-kuum. Udbytte 2,o g (75%), 0¾ = -20° (c-='0,5 i ætanol).The dicyclohexylurea separated in crystalline form is filtered and washed with 10 ml of tetrahydrofuran. The filtrate and washing liquid are combined and evaporated to dryness under reduced pressure. The dry residue is dissolved in hot state in 5 ml of benzene and the resulting solution is poured with stirring into 50 ml of petroleum ether. The resulting suspension is treated with ice for 24 hours after which the product is filtered, washed with 20 ml of cold petroleum ether and dried under vacuum. Yield 2, o g (75%), 0¾ = -20 ° (c - = 0.5 in ethanol).

Claims (2)

6 msn6 msn 1. Analogifremgangsmåde til fremstilling af l-metyl-9,10- dihydro-d-lysergsyreallylamid med formlen oc-nh-ch2-ch=ch2 / n-ch3 Ov “3 eller syreadditionssalte deraf, kendetegnet ved at en reaktiv lysergsyreester med den almene formel ( P-CK3 /O CH3 hvor Z betegner hydrogen- og/eller halogenatomer og/eller nitrogrupper og n betegner et helt tal 1-5, amideres med 1-allylamin eller et syreadditionssalt deraf, hvorefter den dannede forbindelse med formel I om ønsket omdannes til et syreadditionssalt deraf.An analogous process for the preparation of 1-methyl-9,10-dihydro-d-lysergic acid allylamide of the formula oc-nh-ch 2 -ch = ch 2 / n-ch 3 Ov 3 or acid addition salts thereof, characterized in that a Formula (P-CK 3 / O CH 3 where Z represents hydrogen and / or halogen atoms and / or nitro groups and n represents an integer 1-5, is amidated with 1-allylamine or an acid addition salt thereof and then the compound of formula I formed, if desired is converted into an acid addition salt thereof.
DK51373AA 1972-02-04 1973-01-31 Analogous procedure for the preparation of 1-methyl-9,10-dihydro-d-lysergic acid allylamide or acid addition salts thereof. DK141531B (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
HUGO001187 1972-02-04
HUGO001186 HU164051B (en) 1972-02-04 1972-02-04
HUGO001186 1972-02-04
HUGO001187 HU163546B (en) 1972-02-04 1972-02-04

Publications (2)

Publication Number Publication Date
DK141531B true DK141531B (en) 1980-04-14
DK141531C DK141531C (en) 1980-10-06

Family

ID=26318474

Family Applications (1)

Application Number Title Priority Date Filing Date
DK51373AA DK141531B (en) 1972-02-04 1973-01-31 Analogous procedure for the preparation of 1-methyl-9,10-dihydro-d-lysergic acid allylamide or acid addition salts thereof.

Country Status (20)

Country Link
JP (1) JPS5221516B2 (en)
AU (1) AU475943B2 (en)
BE (1) BE794888A (en)
BG (1) BG22832A3 (en)
CA (1) CA994342A (en)
CH (1) CH589079A5 (en)
CS (1) CS191212B2 (en)
DD (1) DD104299A5 (en)
DE (1) DE2305514A1 (en)
DK (1) DK141531B (en)
EG (1) EG10823A (en)
FI (1) FI54118C (en)
FR (1) FR2190440B1 (en)
GB (1) GB1401155A (en)
IL (1) IL41409A (en)
NL (1) NL178256C (en)
NO (1) NO133670C (en)
SE (1) SE421424B (en)
SU (1) SU468419A3 (en)
YU (1) YU36730B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU169073B (en) * 1974-05-28 1976-09-28
HU168914B (en) * 1974-07-30 1976-08-28
HU172649B (en) * 1975-04-24 1978-11-28 Gyogyszerkutato Intezet Process for producing new, biologically active lysergamides
DE2802023A1 (en) * 1977-01-28 1978-08-03 Sandoz Ag NEW ERGOT DERIVATIVES, THEIR PRODUCTION AND USE
JPH0438472U (en) * 1990-07-31 1992-03-31
IT1260156B (en) * 1992-08-03 1996-03-28 Fidia Spa NEURAMINIC ACID DERIVATIVES
US8604035B2 (en) * 2011-06-23 2013-12-10 Map Pharmaceuticals, Inc. Fluoroergoline analogs

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH475252A (en) * 1966-02-08 1969-07-15 Sandoz Ag Process for the production of new lysergic acid derivatives
AT291446B (en) * 1968-11-22 1971-07-12 Richter Gedeon Vegyeszet Process for the preparation of new apovincaminic amides

Also Published As

Publication number Publication date
NL178256C (en) 1986-02-17
AU5163373A (en) 1974-08-01
IL41409A0 (en) 1973-03-30
FI54118B (en) 1978-06-30
EG10823A (en) 1976-07-31
DK141531C (en) 1980-10-06
YU26673A (en) 1982-02-25
SE421424B (en) 1981-12-21
DD104299A5 (en) 1974-03-05
JPS5221516B2 (en) 1977-06-10
FR2190440B1 (en) 1976-09-03
BG22832A3 (en) 1977-04-20
YU36730B (en) 1984-08-31
NL7301369A (en) 1973-08-07
BE794888A (en) 1973-05-29
CH589079A5 (en) 1977-06-30
GB1401155A (en) 1975-07-16
FI54118C (en) 1978-10-10
IL41409A (en) 1977-04-29
AU475943B2 (en) 1976-09-09
SU468419A3 (en) 1975-04-25
NO133670C (en) 1976-06-09
CA994342A (en) 1976-08-03
NL178256B (en) 1985-09-16
DE2305514A1 (en) 1973-08-16
CS191212B2 (en) 1979-06-29
JPS4886900A (en) 1973-11-15
FR2190440A1 (en) 1974-02-01
NO133670B (en) 1976-03-01

Similar Documents

Publication Publication Date Title
DK175205B1 (en) Process for the preparation of 1-adamantane derivatives
DK156826B (en) PROCEDURE FOR THE PREPARATION OF CYCLIC AMINO ACIDS
SU537626A3 (en) Method for producing alkanolamine derivatives
DK141531B (en) Analogous procedure for the preparation of 1-methyl-9,10-dihydro-d-lysergic acid allylamide or acid addition salts thereof.
Elliott 126. The stereochemistry of an oxazoline derivative of threonine. Improvement of a recent threonine synthesis
Wuest et al. Some Derivatives of 3-Pyridol with Parasympathomimetic Properties1
SU747426A3 (en) Method of producing dithienylalkylamines or salts thereof
US3176017A (en) Aroylalkyl derivatives of diazabicyclo-nonanes and-decanes
US3904633A (en) Lysergic amides
US2569415A (en) Imidazolines
SU1493106A3 (en) Method of producing isoxasol derivatives
DK155938B (en) ANALOGY PROCEDURE FOR PREPARING BENZISOXAZOLD DERIVATIVES
SU566521A3 (en) Method of obtaining lactams
NO750278L (en)
NO802101L (en) PROCEDURE FOR PREPARING 15-HYDROXYIMINO-E-HOMO-EBURNAND DERIVATIVES.
US2958691A (en) Certain esters of nu-substituted ethylene imine carboxylic acids and method
US3840534A (en) 4h-furo(3,4-d)(1,3)thiazine-2-phthalimido-2-acetic acid esters
US3378592A (en) Process for the production of 3, 4-dihydroxybenzyloxyaminehydrobromide
SU645572A3 (en) Method of obtaining oxazole derivatives
US2474719A (en) Method for separating the stereoisomers of alpha-hydroxy-beta, beta-dimethylgamma-butyrolactone
US3609179A (en) Lower alkyl 9-carboxylates of 9-(tert.-aminobutynyl) fluorenes
SU585808A3 (en) Method of preparing a-amino-2-adamantyl-acetic acid
SU439964A1 (en) Method for preparing naphthoquinone derivatives
JPS5944312B2 (en) Production method of indazole derivatives
US2660582A (en) Quaternary nicotinic acid amide derivatives and production thereof

Legal Events

Date Code Title Description
PBP Patent lapsed